Dan Netanely

Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study

Boris Katz, S. Levi, S. Trestman, 2021, Therapeutic advances in hematology.